Raju K Pillai
Overview
Explore the profile of Raju K Pillai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Querfeld C, Palmer J, Han Z, Wu X, Yuan Y, Chen M, et al.
Blood Adv
. 2025 Feb;
PMID: 39951620
Selective targeting of the functionally exhausted malignant T cells in cutaneous T-cell lymphoma (CTCL) and distinct cells within the tumor microenvironment (TME) via PD1/PD-L1 blockade (durvalumab) may restore an anti-tumor...
2.
Wu Y, Jin M, Fernandez M, Hart K, Liao A, Ge X, et al.
Blood Cancer Discov
. 2023 Apr;
4(3):228-245.
PMID: 37067905
Significance: METTL3 controls widespread splicing factor abundance via translational control of m6A-modified mRNA, contributes to RNA splicing dysregulation and disease progression in CLL, and serves as a potential therapeutic target...
3.
Zhang J, Wang T, Shetty K, Alkan S, Xu S, Gong Q, et al.
Blood Adv
. 2022 Jun;
6(17):5067-5071.
PMID: 35687491
No abstract available.
4.
Sidhu I, Barwe S, Pillai R, Gopalakrishnapillai A
Cells
. 2021 Oct;
10(10).
PMID: 34685678
In vitro modeling of hematological malignancies not only provides insights into the influence of genetic aberrations on cellular and molecular mechanisms involved in disease progression but also aids development and...
5.
Afkhami M, Ally F, Pullarkat V, Pillai R
Cancer Treat Res
. 2021 Oct;
181:17-43.
PMID: 34626353
Our understanding of the genetics and biology of lymphoblastic leukemia/lymphoma (acute lymphoblastic leukemia, ALL) has advanced rapidly in the past decade with advances in sequencing and other molecular techniques. Besides...
6.
Pillai R, Afkhami M
Cancer Treat Res
. 2021 Oct;
181:1-16.
PMID: 34626352
Advances in high-throughput DNA sequencing technology in the past decade have made a tremendous impact on basic science and clinical practice. Methods using the latest next generation sequencing technology can...
7.
Reckamp K, McQuerry J, Mambetsariev I, Pharaon R, Yost S, Fricke J, et al.
Future Sci OA
. 2021 Jan;
7(2):FSO662.
PMID: 33437521
The implication of alterations in solid tumors and the immune microenvironment remains elusive. Formalin-fixed, paraffin-embedded samples of 21 patients with solid tumors harboring alterations were used for immunohistochemical staining. Extracted...
8.
Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Jun;
19(7):e400-e405.
PMID: 31155409
Background: Mutations in isocitrate dehydrogenase (IDH)1/2 genes result in nicotinamide adenine dinucleotide phosphate-dependent reduction of α-ketoglutarate and formation of 2-hydroxyglutarate, which blocks normal cellular differentiation and promotes leukemogenesis. Nearly 20%...
9.
Zhao X, Zhang Z, Moreira D, Su Y, Won H, Adamus T, et al.
Mol Ther
. 2018 Feb;
26(3):695-707.
PMID: 29433938
Growing evidence links the aggressiveness of non-Hodgkin's lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling....
10.
Yuan Y, Kos F, He T, Yin H, Li M, Hardwick N, et al.
Oncoimmunology
. 2017 Dec;
6(12):e1363138.
PMID: 29209571
A heavily pretreated patient with triple negative breast cancer distinguished by cutaneous metastases received p53MVA vaccine in combination with pembrolizumab. Her cutaneous metastases regressed and after 2 cycles of therapy,...